A start-up company in Philadelphia has raised $10 million to develop pharmaceuticals to treat sleep apnea and other breathing control conditions.
Galleon Pharmaceuticals was founded in 2003 by CEO and President James Mannion, who has spent 25 years in the pharmaceuticals industry. In 2006, Galleon licensed the underlying technology for its drugs from the University of Louisville, where it was discovered by David Gozal, MD, a professor and vice chair of research in the pediatrics department of the university's medical school.
Mannion has a patent for a combination drug that includes S-nitrosothiol, a compound involved in several steps of the breathing process that can trigger the body's normal response to low oxygen levels, causing increases in the rate and depth of breathing. Sleep apnea is a primary therapeutic target for the drug.
Copyright © 2010 DrBicuspid.com
